Review
Oncology
Ying Zhang, Amit Sharma, Hans Weiher, Matthias Schmid, Glen Kristiansen, Ingo G. H. Schmidt-Wolf
Summary: Lymphoma, a heterogeneous cancer with over 70 subtypes, shows potential for immunotherapy like CIK cell therapy. Optimizing personalized approaches, including using CIK cells and other immune modules, may improve therapeutic outcomes in lymphomas, which continue to see expanding treatment options.
Review
Cell Biology
Farimah Fayyaz, Niloufar Yazdanpanah, Nima Rezaei
Summary: This review summarizes the clinical studies on the safety and efficacy of CIK cell therapy in treating CRC. The combination of CIK cells and chemotherapy appears to be beneficial for CRC patients, and potential signaling pathways and methods for improving migration abilities are discussed.
CELL COMMUNICATION AND SIGNALING
(2022)
Review
Medicine, General & Internal
Xin Yuan, An Zhi Zhang, Yi Lin Ren, Xue Li Wang, Chen Hao Jiang, Lan Yang, Chun Xia Liu, Wei Hua Liang, Li Juan Pang, Wen Yi Gu, Feng Li, Jian Ming Hu
Summary: Combination chemotherapy with CIK/DC-CIK immunotherapy shows significant efficacy and safety in the treatment of esophageal cancer, improving antitumor immune responses and quality of life. Immunotherapy increases specific cell subsets, cytokines, and immunoglobulin levels, enhancing immune function in patients.
Review
Biochemistry & Molecular Biology
Ewa Wrona, Maciej Borowiec, Piotr Potemski
Summary: CAR-NK cells have emerged as a potential treatment for malignant tumors, offering a lower cost and broader availability for infusion compared to CAR-T cells. Research indicates that CAR-NK cells are effective against both hematological and non-hematological malignancies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Immunology
Xiaolong Wu, Amit Sharma, Johannes Oldenburg, Hans Weiher, Markus Essler, Dirk Skowasch, Ingo G. H. Schmidt-Wolf
Summary: CIK cells are a promising candidate for immunotherapy due to their convenient and relatively inexpensive expansion capability. NKG2D plays a crucial role in CIK cell-mediated antitumor activity, with NKG2D engagement alone being sufficient to activate CIK cells. The role of 2B4 in CIK cells is still unclear, but it provides limited synergy with NKG2D in certain aspects. Additional research is needed to optimize the functional potential of CIK cells for cancer therapy.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Immunology
Yesim Eralp, Utku Ates
Summary: Malignant neoplasms from the GI tract are common and highly fatal. Immunotherapy has limited efficacy in GI cancer, except for a small subgroup. The evaluation of various immunotherapy approaches is ongoing to find more effective treatment options.
Article
Biochemistry & Molecular Biology
Francesca Garofano, Amit Sharma, Hinrich Abken, Maria A. Gonzalez-Carmona, Ingo G. H. Schmidt-Wolf
Summary: Through studying the role of the cannabinoid system in cancer development, it has been found that cannabidiol can enhance the cytotoxicity of killer cells without any associated side effects. This combinatorial approach with immune system cells shows potential for clinical treatment of pancreatic cancer.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Oncology
Julian Burks, Purevdorj B. Olkhanud, Jay A. Berzofsky
Summary: Gastrointestinal cancers are a group of complex cancers that affect the digestive system. NKT cells, with their immunoregulatory properties, play a crucial role in tumor immunity and can have either anti-tumor or pro-tumor effects depending on the cytokine profile expressed and the type of GI cancer.
Review
Oncology
Keywan Mortezaee, Jamal Majidpoor
Summary: NK cells, as lymphoid cells of innate immunity, play important roles in immune surveillance and immunotherapy. However, the decreased cytotoxic activity and reduced number of activating receptors limit their application in cellular immunotherapy.
Review
Cell & Tissue Engineering
Mubin Tarannum, Rizwan Romee
Summary: NK cells can exhibit memory-like features, altering their lifespan and function through cytokine-induced methods to enhance anticancer effects. Current research indicates that these memory-like NK cells have great potential for clinical applications.
STEM CELL RESEARCH & THERAPY
(2021)
Article
Chemistry, Multidisciplinary
Taehoon Sim, Bongseo Choi, Soon Woo Kwon, Kwang-Soo Kim, Hyunjun Choi, Alexander Ross, Dong-Hyun Kim
Summary: This study addresses the issue of poor clinical efficacy of NK cells against established solid tumors by preparing magnetic nanocomplexes HAPF for effective labeling and magneto-activation of NK cells, as well as the MRI contrast effect of NK cells, thereby improving the therapeutic effect of NK cell treatment for cancer.
Article
Immunology
Xinyi Yang, Desheng Weng, Qiuzhong Pan, Tong Xiang, Chaopin Yang, Zhengrong Wu, Minxing Li, Songzuo Xie, Yan Tang, Jianchuan Xia, Jingjing Zhao
Summary: This study investigated the use of adjuvant cellular immunotherapy in post-mastectomy breast cancer patients. The results showed that patients treated with cellular immunotherapy had a higher overall survival rate compared to those who did not receive the treatment, particularly those who received NK cell immunotherapy. Subgroup analyses also indicated that adjuvant cellular immunotherapy significantly improved the overall survival of patients with triple-negative breast cancer and those aged over 50 years.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Wu Wang, Xi Wang, Wenli Yang, Kai Zhong, Na He, Xuexia Li, Yanyang Pang, Zi Lu, Aiqun Liu, Xiaoling Lu
Summary: The study showed that stimulation with the CTLA-4 specific nanobody Nb36 resulted in enhanced anti-tumor effects of DC-CIK cells both in vitro and in vivo, significantly inhibiting tumor growth and extending the survival of tumor-bearing mice.
Article
Oncology
Elisabeth M. P. Steeghs, Hans Gelderblom, Vincent K. Y. Ho, Quirinus J. M. Voorham, Stefan M. Willems, Katrien Grunberg, Marjolijn J. L. Ligtenberg
Summary: The study found that in the Netherlands, predictive mutation analysis is mainly conducted in high-risk or metastatic GIST patients, with a higher testing rate in patients treated at expertise centers. However, not all patients who have received imatinib therapy have received mutation-tailored treatment according to the guidelines.
Article
Chemistry, Multidisciplinary
Xinyue Wang, Fanyan Meng, Xiang Li, Luxin Xue, Anni Chen, Yuling Qiu, Zhifan Zhang, Lin Li, Fengcen Liu, Yishan Li, Zhichen Sun, Yanhong Chu, Ruihan Xu, Lixia Yu, Jie Shao, Manman Tian, Xiaoping Qian, Qin Liu, Baorui Liu, Rutian Li
Summary: Chimeric antigen receptor (CAR)-T cell therapy is an effective treatment against advanced malignancies, but it can cause severe adverse events. A nanomodified switch strategy using gelatinase-responsive nanoparticles (NPs) selectively delivers a heterodimerizing switch to activate CAR-T cells only on tumors. The sustained-release effect of NPs ensures smooth activation of CAR-T cells, avoiding sudden cytokine release. This study introduces NanoSwitch as a universal and applicable solution for safety problems in CAR-T therapy.